ArticleAnnals of neurology2026
Effects of an Inpatient Program on Medication Errors in Hospitalized People with Parkinson's Disease.
Article in Annals of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHospitalized people with Parkinson's disease (PwP) face increased risks of medication errors and discharge to non-home settings, both of which are associated with adverse outcomes. This study assessed differences in medication error rates and discharge outcomes before and after implementation of a dedicated inpatient program for hospitalized PwP.
methodsDuring 2023, a Parkinson's disease (PD) inpatient program was implemented and refined combining: (1) an electronic health record (EHR) census for identification of hospitalized PwP; (2) inpatient monitoring and alignment of inpatient and outpatient regimens by movement-disorders-trained advanced practitioners; (3) customized EHR alerts and levodopa orders; (4) pharmacist support, and (5) staff education. Medication error rates and clinical outcomes were compared between January and June 2024 (post-implementation phase) and a pre-implementation retrospective cohort from 2018.
resultsFrom January to June 2024, 366 post-implementation admissions were monitored. Among those receiving contraindicated medications, the median number of doses decreased from 2 (interquartile range [IQR] = 1-6) during pre-implementation to 1 (IQR: 1-2) post-implementation (p = 0.015). Days with a levodopa dose deviation decreased from 43.1% to 38.3%, p < 0.0001, improper levodopa formulation substitutions from 18.6% to 5%, p < 0.0001, timing deviations from 72.2% to 51.8%, p < 0.00001, missed doses from 21.5% to 16.8%, p = 0.013, and discharged to non-home settings from 44.8% to 38.3%, p = 0.038.
interpretationFollowing implementation of a multidisciplinary and proactive inpatient program, reductions in medication errors and improved discharge outcomes were observed among PwP. ANN NEUROL 2026;100:1068-1079.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.